NASDAQ:DRTS Alpha Tau Medical Q2 2026 Earnings Report $14.40 -0.04 (-0.24%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alpha Tau Medical EPS ResultsActual EPS-$0.50Consensus EPS -$0.14Beat/MissMissed by -$0.36One Year Ago EPSN/AAlpha Tau Medical Revenue ResultsActual RevenueN/AExpected Revenue$0.14 millionBeat/MissN/AYoY Revenue GrowthN/AAlpha Tau Medical Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time4:00PM ETUpcoming EarningsAlpha Tau Medical's Q3 2026 earnings is estimated for Thursday, November 19, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Alpha Tau Medical Earnings HeadlinesOramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And MoreSeptember 11 at 5:00 PM | seekingalpha.comAlpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM BreakthroughSeptember 4, 2026 | seekingalpha.comMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by robots but by America's oil and gas infrastructure. It's called the Patriot Income Plan, or P.I.P., and it pays 10% a year across 42 separate distribution dates. This year it's on track to pay out a record 53 billion dollars. Think of it as a personal stake in the world's largest energy producer, structured to deliver income on a regular schedule.September 14 at 1:00 AM | Freedom Financial (Ad)Alpha Tau to Participate in September Investor ConferencesSeptember 2, 2026 | globenewswire.comAlpha Tau Completes Enrollment in IMPACT Pancreatic Cancer Pilot Study of Alpha DaRTAugust 31, 2026 | tipranks.comAlpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple ExpansionsAugust 31, 2026 | globenewswire.comSee More Alpha Tau Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email. Email Address About Alpha Tau MedicalAlpha Tau Medical (NASDAQ:DRTS) is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue. Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells. The company has evaluated the technology in clinical studies across several cancer indications, including cutaneous squamous cell carcinoma and other solid tumors. Alpha Tau was founded in Israel and has conducted research and clinical development activities in Israel, the United States and other international locations. The company is led by Chief Executive Officer Uzi Sofer and continues to focus on advancing Alpha DaRT through clinical development and potential regulatory approval for cancer treatment.View Alpha Tau Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Kings to Buy While They’re Still Beaten DownMarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundThe End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing SharesFabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.